ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1936

The Human Leukocyte Antigen DRB1*13:02-DQB1*06:04-DPB1*04:01 Haplotype Is Closely Associated with Dermatomyositis Patients with Anti-CADM-140 (Melanoma Differentiation-Associated Protein 5: MDA5) Antibody

Yuji Hosono1, Chikashi Terao2, Ran Nakashima1, Yoshitaka Imura3, Naoichiro Yukawa4, Hajime Yoshifuji1, Motomu Hashimoto5, Koichiro Ohmura6, Takao Fujii7 and Tsuneyo Mimori1, 1Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 2Center for Genomic Medicine, Kyoto University, Kyoto, Japan, 3Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 4Dept of Rheum & Clinical Immun, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 5The Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 6Rheumatology & Clin Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 7Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Antibodies, dermatomyositis and human leukocyte antigens (HLA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Muscle Biology, Myositis and Myopathies: Genetics, Autoantibodies and other Molecular Aspects of Idiopathic Inflammatory Myopathies and Models

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Recent studies have revealed that anti-CADM-140 (MDA5/IFIH1)-antibody positive dermatomyositis (DM) patients frequently develop acute or subacute progressive interstitial pneumonia (A/SIP) with poor prognosis. However, genetic background of anti-CADM-140-antibody positive DM is currently unclear. Here, we intended to analyze the relationship between specific human leukocyte antigen (HLA) alleles in anti-CADM-140-positive DM patients.

Methods:

Anti-CADM-140-antibody positive DM patients (CADMs, N=20) and healthy controls (HCs, N=2972) were enrolled in this study. Autoantibodies were screened using immunoprecipitation with [35S]methionine-labelled HeLa cells. HLA class I (A, B, and C) and class II (DRB1, DQA1, DQB1, and DPB1) genotyping was carried out with a highthroughput, high-resolution genotyping method (WAKFlow WAKUNAGA) by combining PCR and sequence-specific oligonucleotide probe protocols with the Luminex 100 xMAP flow cytometry dual-laser system to quantify fluorescently labelled oligonucleotides attached to colour-coded microbeads.Allele frequency was compared between CADMs and HCs by chi-square test or Fisher’s exact test. Haplotypes with frequency more than 10% in CADMs were analyzed for comparison between CADMs and HCs with chi-square test.

Results:

No specific HLA class I alleles show significant associations with CADMs.CADMs demonstrated higher allele frequencies of DRB1*1302 (15% vs 5.5%; with OR=2.73,0.0854), DQB1*0604 (12.5% vs 5.5%; with OR=2.5,P= 0.0114), and DPB1*0401 (12.5% vs 5%�G with OR=2.5,P= 0.03469) than HCs. However, no specific HLA alleles reached significant difference between CADMs and NCs due to lack of power. The observed distribution of HLA class II alleles among patients and controls suggested the notion that specific combinations of alleles at the DRB1, DQB1, and DPB1 loci are associated with the risk for CADMs. Haplotype analysis showed the frequency of the haplotype DRB1*13:02-DQB1*06:04-DPB1*04:01 was higher in CADMs than NCs (12.5% vs 3.6%;OR 3.79, 95%CI 1.47-9.76, P = 0.0030).

Conclusion:

HLA-DRB1*13:02-DQB1*06:04-DPB1*04:01 haplotype is closely associated with CADMs,suggesting that the production of anti-CADM-140 may be associated with a certain immunogenetive background.


Disclosure:

Y. Hosono,
None;

C. Terao,
None;

R. Nakashima,
None;

Y. Imura,
None;

N. Yukawa,
None;

H. Yoshifuji,
None;

M. Hashimoto,
None;

K. Ohmura,
None;

T. Fujii,
None;

T. Mimori,

Medical & Biological Laboratories, Co., Ltd.,

2,

Medical & Biological Laboratories, Co., Ltd,

8.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-human-leukocyte-antigen-drb11302-dqb10604-dpb10401-haplotype-is-closely-associated-with-dermatomyositis-patients-with-anti-cadm-140-melanoma-differen/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology